View printer-friendly version
- Granted Priority Medicines designation by the
-More than 30 patients have been dosed with CTX001 across CLIMB-Thal-111 and CLIMB-SCD-121 to date; completion of enrollment in both trials is expected in 2021-
-Enrollment ongoing in CTX110™, CTX120™ and CTX130™ clinical trials-
“We continue to make progress across our hemoglobinopathies and immuno-oncology programs on the clinical front, and expect to disclose data on multiple programs in 2021,” said
Recent Highlights and Outlook
- Beta Thalassemia and Sickle Cell Disease
European Medicines Agencygranted Priority Medicines (PRIME) designation to CTX001™, an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy for the treatment of transfusion-dependent beta thalassemia (TDT). CTX001 was previously granted PRIME designation for the treatment of sickle cell disease (SCD) in 2020.
- Enrollment and dosing are ongoing in the clinical trials for CTX001. More than 30 patients have been dosed with CTX001 across both trials to date. Completion of enrollment in both trials is expected in 2021.
- The Company expects to report additional data in 2021 from its ongoing Phase 1 CARBON trial assessing the safety and efficacy of several dose levels of CTX110, its wholly-owned allogeneic chimeric antigen receptor T cell (CAR-T) investigational therapy targeting CD19, for the treatment of relapsed or refractory B-cell malignancies.
- CRISPR Therapeutics’ Phase 1 clinical trial assessing the safety and efficacy of several dose levels of CTX120, its wholly-owned allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma, is ongoing. The Company expects to report top-line data from this trial in 2021.
- CRISPR Therapeutics’ two independent Phase 1 clinical trials assessing the safety and efficacy of several dose levels of CTX130, its wholly-owned allogeneic CAR-T investigational therapy targeting CD70, for the treatment of both solid tumors and certain hematologic malignancies, are ongoing. The Company expects to report top-line data from these trials in 2021. Earlier this month, the Company announced preclinical data from its CAR-T program at the
American Association for Cancer Research(AACR) Annual Meeting 2021. The data, presented in an e-poster session entitled, “CD70 knockout: A novel approach to augment CAR-T cell function, found that the generation of CAR-T cells including knockout of the CD70 show improved properties, including potency and persistence over CAR-T cells where the CD70 gene remains intact.”
- Regenerative Medicine
CRISPR Therapeuticsand its partner ViaCyteremain on track to initiate a Phase 1/2 trial of their allogeneic stem cell-derived therapy for the treatment of Type 1 diabetes in 2021. The combination of ViaCyte’s stem cell capabilities and CRISPR’s gene editing capabilities has the potential to enable a beta-cell replacement product that may deliver durable benefit to patients without requiring immune suppression.
- Other Corporate Matters
- Earlier this month,
CRISPR Therapeuticsand its partner Vertex announced that the companies have amended their collaboration agreement to develop, manufacture and commercialize CTX001. Under the terms of the amended agreement, CRISPR Therapeuticswill be responsible for 40% of the program costs and will receive 40% of the profits from future sales of CTX001 worldwide. With this revised agreement, Vertex will deploy the breadth of its established global capabilities and proven experience in development, manufacturing, and commercialization to maximize the potential for CTX001 to transform the lives of tens of thousands of patients in the U.S., Europeand other countries. CRISPR Therapeuticswill continue to support the development of CTX001 and invest in further innovation to maximize its potential. The transaction is subject to customary closing conditions and clearances, including clearance under the Hart-Scott Rodino Antitrust Improvements Act.
- Earlier this month,
First Quarter 2021 Financial Results
- Cash Position: Cash, cash equivalents and marketable securities were
$1,806.2 millionas of March 31, 2021, compared to $1,690.3 millionas of December 31, 2020. The increase in cash of $115.9 millionwas primarily driven by cash from financing activities of $226.0 million, which consists primarily of proceeds received from sales under our “at-the-market” offering in January and early February of 2021 offset by continuing operating expenses.
- Revenue: Total collaboration revenue was
$0.2 millionfor the first quarter of 2021 compared to $0.2 millionfor first quarter of 2020. Collaboration revenue primarily consisted of charges to partners for research activities.
- R&D Expenses: R&D expenses were
$90.6 millionfor the first quarter of 2021 compared to $54.2 millionfor the first quarter of 2020. The increase in expense was driven by development activities supporting the advancement of the hemoglobinopathies program and wholly-owned immuno-oncology programs, as well as increased headcount and supporting facilities related expenses.
- G&A Expenses: General and administrative expenses were
$24.5 millionfor the first quarter of 2021 compared to $19.6 millionfor the first quarter of 2020. The increase in general and administrative expenses for the year was primarily driven by headcount-related expense.
- Net Income/Loss: Net loss was
$113.2 millionfor the first quarter of 2021 compared to a net loss of $69.7 millionfor the first quarter of 2020.
CTX001 is an investigational, autologous, ex vivo CRISPR/Cas9 gene-edited therapy that is being evaluated for patients suffering from TDT or severe SCD, in which a patient’s hematopoietic stem cells are edited to produce high levels of fetal hemoglobin (HbF; hemoglobin F) in red blood cells. HbF is a form of the oxygen-carrying hemoglobin that is naturally present at birth, which then switches to the adult form of hemoglobin. The elevation of HbF by CTX001 has the potential to alleviate transfusion requirements for patients with TDT and reduce painful and debilitating sickle crises for patients with SCD.
Based on progress in this program to date, CTX001 has been granted Regenerative Medicine Advanced Therapy (RMAT), Fast Track, Orphan Drug, and Rare Pediatric Disease designations from the
About the CRISPR-Vertex Collaboration
The ongoing Phase 1/2 open-label trial, CLIMB-Thal-111, is designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 12 to 35 with TDT. The trial will enroll up to 45 patients and follow patients for approximately two years after infusion. Each patient will be asked to participate in a long-term follow-up trial.
The ongoing Phase 1/2 open-label trial, CLIMB-SCD-121, is designed to assess the safety and efficacy of a single dose of CTX001 in patients ages 12 to 35 with severe SCD. The trial will enroll up to 45 patients and follow patients for approximately two years after infusion. Each patient will be asked to participate in a long-term follow-up trial.
CTX110, a wholly owned program of
The ongoing Phase 1 single-arm, multi-center, open label clinical trial, CARBON, is designed to assess the safety and efficacy of several dose levels of CTX110 for the treatment of relapsed or refractory B-cell malignancies.
CTX120, a wholly-owned program of
CTX130, a wholly-owned program of
CRISPR Therapeutics Forward-Looking Statement
This press release may contain a number of “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements made by Dr. Kulkarni in this press release, as well as statements regarding CRISPR Therapeutics’ expectations about any or all of the following: (i) the safety, efficacy and clinical progress of CRISPR Therapeutics’ various clinical programs, including CTX001, CTX110, CTX120 and CTX130; (ii) the status of clinical trials and preclinical studies (including, without limitation, the expected timing of data releases and development, as well as completion of clinical trials) and development timelines for CRISPR Therapeutics’ product candidates; (iii) the data that will be generated by ongoing and planned clinical trials, and the ability to use that data for the design and initiation of further clinical trials, including expectations regarding the CTX001 and CTX110 data and CAR-T CD70 preclinical data; (iv) the actual or potential benefits of regulatory designations; (v) the timing of the potential closing of the transaction contemplated by the amended collaboration agreement, future activities of the parties pursuant to the collaboration and the potential benefits of CRISPR Therapeutics’ collaboration with Vertex, as well as other partners; (vi) the intellectual property coverage and positions of CRISPR Therapeutics, its licensors and third parties as well as the status and potential outcome of proceedings involving any such intellectual property; (vii) the sufficiency of CRISPR Therapeutics’ cash resources; and (viii) the therapeutic value, development, and commercial potential of CRISPR/Cas9 gene editing technologies and therapies. Without limiting the foregoing, the words “believes,” “anticipates,” “plans,” “expects” and similar expressions are intended to identify forward-looking statements. You are cautioned that forward-looking statements are inherently uncertain. Although CRISPR Therapeutics believes that such statements are based on reasonable assumptions within the bounds of its knowledge of its business and operations, forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those projected or suggested in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the potential for initial and preliminary data from any clinical trial and initial data from a limited number of patients not to be indicative of final trial results; the potential that clinical trial results may not be favorable; that one or more of CRISPR Therapeutics’ internal or external product candidate programs will not proceed as planned for technical, scientific or commercial reasons; that future competitive or other market factors may adversely affect the commercial potential for CRISPR Therapeutics’ product candidates; uncertainties inherent in the initiation and completion of preclinical studies for CRISPR Therapeutics’ product candidates (including, without limitation, availability and timing of results and whether such results will be predictive of future results of the future trials); uncertainties about regulatory approvals to conduct trials or to market products; the potential impacts due to the coronavirus pandemic such as (x) delays in regulatory review, manufacturing and supply chain interruptions, adverse effects on healthcare systems and disruption of the global economy; (y) the timing and progress of clinical trials, preclinical studies and other research and development activities; and (z) the overall impact of the coronavirus pandemic on its business, financial condition and results of operations; uncertainties regarding the intellectual property protection for CRISPR Therapeutics’ technology and intellectual property belonging to third parties, and the outcome of proceedings (such as an interference, an opposition or a similar proceeding) involving all or any portion of such intellectual property; and those risks and uncertainties described under the heading "Risk Factors" in CRISPR Therapeutics’ most recent annual report on Form 10-K and in any other subsequent filings made by CRISPR Therapeutics with the U.S. Securities and Exchange Commission, which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date they are made. CRISPR Therapeutics disclaims any obligation or undertaking to update or revise any forward-looking statements contained in this press release, other than to the extent required by law.
Real Chemistry on behalf of CRISPR
Condensed Consolidated Statements of Operations
(Unaudited, In thousands except share data and per share data)
|Three Months Ended
|Research and development||90,565||54,193|
|General and administrative||24,517||19,550|
|Total operating expenses||115,082||73,743|
|Loss from operations||(114,543||)||(73,586||)|
|Total other income (expense), net||1,955||4,232|
|Net loss before income taxes||(112,588||)||(69,354||)|
|Provision for income taxes||(575||)||(377||)|
|Foreign currency translation adjustment||5||(25||)|
|Unrealized loss on marketable securities||(383||)||—|
|Net loss per common share — basic||$||(1.51||)||$||(1.15||)|
|Basic weighted-average common shares outstanding||75,005,187||60,847,683|
|Net loss per common share — diluted||$||(1.51||)||$||(1.15||)|
|Diluted weighted-average common shares outstanding||75,005,187||60,847,683|
Condensed Consolidated Balance Sheets Data
(Unaudited, in thousands)
|Total shareholders' equity||1,805,498||1,664,234|
Source: CRISPR Therapeutics AG